Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
Status:
Terminated
Trial end date:
2018-11-16
Target enrollment:
Participant gender:
Summary
This is a single center, open label, phase I study involving grade I-III
gastroenteropancreatic neuroendocrine tumors, consisting of a dose escalation Part A followed
by an expansion cohort Part B. On Part A Patients will be treated with daily oral everolimus.
Fosbretabulin will be administered IV either q3 weekly or q weekly based on PO CRM cohort.
Part B: Once the investigators have established an MTD in Part A, the investigators will be
treating 15 more patients at that dose combination. The primary and secondary objectives of
the expansion cohort will be similar to Part A of the study, i.e., to establish a safety
profile of the experimental drug combination and to collect and assess efficacy data.
Patients will be treated with concurrent everolimus and fosbretabulin for 12 weeks.